Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04555187 · ClinicalTrials.gov registry record
Cardiovascular Risk Stratification in Covid-19
A clinical trial, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- 1,355
- Enrollment target
NCT04555187: Completed study, sponsored by Oregon Health and Science University.
NCT04555187 is a clinical trial that has completed, run by Oregon Health and Science University. The registered enrollment target is 1,355 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04555187 has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- 1,355 participants
- Enrollment target
Study Summary
This retrospective double-cohort study seeks to: 1. Describe the cardiovascular manifestations and electrophysiological (EP) substrate in COVID-19 infection and their association with clinical outcomes; and 2. Develop a method of cardiovascular risk stratification in COVID-19
Primary Outcome
Number and rate of persons with composite of all-cause death, critical care utilization (ICU bed), development of a life-threatening arrhythmia (ventricular tachycardia/ventricular fibrillation or sudden cardiac arrest), acute heart failure, myocardial infarction (STEMI, NSTEMI, or silent MI), or incident stroke, whichever comes first.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,355 participants |
| Start Date | 2020-06-08 |
| Est. Completion | 2021-12-01 |
What the finished NCT04555187 record still lists
NCT04555187 is an observational study that tracks outcomes without assigning an intervention. Its 1,355 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04555187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04555187 about?
NCT04555187 is a clinical study titled "Cardiovascular Risk Stratification in Covid-19". This retrospective double-cohort study seeks to: 1. Describe the cardiovascular manifestations and electrophysiological (EP) substrate in COVID-19 infection and their association with clinical outcomes; and 2. Develop a method of cardiovascular risk stratification in COVID-19
What is the current status of trial NCT04555187?
This trial is currently completed. The enrollment target is 1,355 participants. The study started on 2020-06-08. Estimated completion is 2021-12-01.
Who is sponsoring clinical trial NCT04555187?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI